October 9, 2025
In this guest blog post, Sarah Khor, Director, International Government Affairs & Policy at Amgen (EUCOPE member) explains why World Sight Day is a reminder that innovation and rare eye diseases go hand-in-hand with Europe’s competitiveness ambitions. There are more… read more
September 24, 2025
Why Europe Needs a Biotech Act By Nicholas Cosenza, Head of EU Government Affairs, Amgen Biotechnology harnesses biological systems—often using living cells and organisms—to develop innovative therapies, tools, and technologies that address some of the most complex health challenges. In… read more
June 4, 2025
Improving the Paediatric Framework: Aligning Ambition with Reality in the Revision of the General Pharmaceutical Legislation As part of the broader revision of the EU’s General Pharmaceutical Legislation (GPL), the integration and update of the Paediatric Regulation is a timely… read more
May 27, 2025
In this guest blog post, Sarah Khor, Director, International Government Affairs & Policy at Amgen (EUCOPE member) sets out why the recently adopted WHA Resolution on rare diseases is an opportunity not to be missed for Europe. The adoption of… read more
February 27, 2025
Building on a previous blog on the need to reduce medicine approval timelines, it is imperative that all Orphan Medicinal Products (OMPs) be eligible for consideration under the EMA’s Priority Medicines (PRIME) scheme as part of the Revised General Pharmaceutical… read more